Consistently, our findings on ovarian cancer reveal higher prevalences of BRCA1 and BRCA2 mutations in subtypes 1 and 3, which are associated with better survival and responses to treatments compared to subtype 2 (Figure 6c). The gene discussed is BRCA2; the disease is ovarian carcinoma.